Evotec (NASDAQ:EVO) Price Target Raised to $14.00 at HC Wainwright

Evotec (NASDAQ:EVOFree Report) had its target price upped by HC Wainwright from $12.00 to $14.00 in a report released on Thursday morning, MarketBeat Ratings reports. HC Wainwright currently has a buy rating on the stock.

Evotec Trading Down 0.3 %

Shares of EVO opened at $11.81 on Thursday. Evotec has a 12-month low of $7.80 and a 12-month high of $13.49. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.09 and a current ratio of 3.18.

About Evotec

(Get Free Report)

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.

See Also

Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.